IPPC: Why You Should Be There

OBTNFebruary 2010
Volume 4
Issue 2

The Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) will take place on Saturday March 27, 2010, in New York City.

The Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) will take place on Saturday March 27, 2010, in New York City. Judy Lum, ArcMesa Educators, said seating is limited and filling up quickly, so medical professionals should sign up without delay if they plan to attend—and there are many reasons why they should attend.

“This is one of the few conferences fully dedicated to prostate cancer that emphasizes an interdisciplinary approach. The rapid pace of research and emerging treatment options in prostate cancer has created a real need for a conference like the IPCC, to help translate discovery into practice,” said Robert Dreicer, MD, a presenter at the meeting. “This symposium brings together a panel of experts, all heavily involved in both clinical care and research, to help satisfy this unmet need, which is most evident in castrate-resistant prostate cancer. This is an area where a lot of resources have been invested and shepherding advances from the conference hall to the clinic is critical.”

The physicians scheduled to present at the IPCC are well known in the field of prostate cancer:

Co-chair Leonard G. Gomella, MD, from the Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania;

Co-chair Daniel P. Petrylak, MD, with the Herbert Irving Comprehensive Cancer Center, Columbia University/New York Presbyterian Hospital;

E. Roy Berger, MD, Stony Brook University School of Medicine in New York;

E. David Crawford, MD, from Denver’s University of Colorado Health Sciences Center;

Robert Dreicer, MD, Taussig Cancer Institute, Cleveland Clinic, and the Cleveland Clinic Lerner College of Medicine in Ohio; and

Howard M. Sandler, MD, MS, Cedars-Sinai Medical Center, in Los Angeles, California.

The speakers will review current practice guidelines adopted by the American Urological Association, the National Comprehensive Cancer Network, and the American Society of Clinical Oncology. Part of the discussion will address how these sets of guidelines differ from one another and how physicians should reconcile those differences in practice.

Oncology & Biotech News

The panel will summarize recent clinical data for emerging therapeutic strategies in prostate cancer, including immunotherapy, and review their associated challenges in clinical application. The Congress will conclude with a case-based roundtable discussion focused on encouraging an interdisciplinary approach to managing prostate cancer. For more information on the IPCC and to sign up, visit http://www.arcmesa.org. will be providing full coverage of the conference online at www.onclive.com and in our May issue.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.